Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study

Wang, XiuzheDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden; Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (författare)

Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells : the OmegAD study

Funding agencies:Pronova Biocare A/SChinese Scholarship CouncilSwedish Alzheimer Foundation
Specialized proresolving mediators (SPMs) induce resolution of inflammation. SPMs are derivatives of n-3 and n-6 PUFAs and may mediate their beneficial effects. It is unknown whether supplementation with PUFAs influences the production of SPMs. Alzheimer's disease (AD) is associated with brain inflammation and reduced levels of SPMs. The OmegAD study is a randomized, double-blind, and placebo-controlled clinical trial on AD patients, in which placebo or a supplement of 1.7 g DHA and 0.6 g EPA was taken daily for 6 months. Plasma levels of arachidonic acid decreased, and DHA and EPA levels increased after 6 months of n-3 FA treatment. Peripheral blood mononuclear cells (PBMCs) were obtained before and after the trial. Analysis of the culture medium of PBMCs incubated with amyloid-β 1-40 showed unchanged levels of the SPMs lipoxin A4 and resolvin D1 in the group supplemented with n-3 FAs, whereas a decrease was seen in the placebo group. The changes in SPMs showed correspondence to cognitive changes. Changes in the levels of SPMs were positively correlated to changes in transthyretin. We conclude that supplementation with n-3 PUFAs for 6 months prevented a reduction in SPMs released from PBMCs of AD patients, which was associated with changes in cognitive function.

Hjorth, ErikKarolinska Institutet (författare)
Vedin, IngerKarolinska Institutet (författare)
Eriksdotter, MariaKarolinska Institutet (författare)
Freund-Levi, Yvonne,1956-Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden(Swepub:oru)yfi (författare)
Wahlund, Lars-OlofKarolinska Institutet (författare)
Cederholm, TommyKarolinska Institutet,Uppsala universitet,Klinisk nutrition och metabolism(Swepub:uu)tomce419 (författare)
Palmblad, JanKarolinska Institutet (författare)
Schultzberg, MarianneKarolinska Institutet (författare)
Karolinska InstitutetDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Stockholm, Sweden; Department of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (creator_code:org_t)

Ingår i:Journal of Lipid Research: American Society for Biochemistry and Molecular Biology56:3, s. 674-6810022-22751539-7262

Av författaren/redakt...: Wang, Xiuzhe; Hjorth, Erik; Vedin, Inger; Eriksdotter, Mar ...; Freund-Levi, Yvo ...; Wahlund, Lars-Ol ...; visa fler...; Cederholm, Tommy; Palmblad, Jan; Schultzberg, Mar ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinsk biotek ...; och Medicinsk biotek ...

Av lärosätet: Örebro universitet; Uppsala universitet; Karolinska Institutet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.